article thumbnail

STS Announces Late-breaker Research to Be Presented at the 2024 Annual Meeting

DAIC

milla1cf Mon, 01/29/2024 - 11:00 January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio. The analysis included 4,798 patients from 207 STS sites who underwent esophagectomy between 2012-2019.

Research 111
article thumbnail

New Tool Helps Predict Stroke Outcome with Higher Accuracy

DAIC

29, 2025 Researchers atOchsner Health, led byHernan Bazan, MD, DFSVS, FACS, have developed a predictive model with a 93% accuracy rate in determining whether urgent carotid-intervention patients will regain functional independence. tim.hodson Thu, 01/30/2025 - 15:31 Jan.

Stroke 52
article thumbnail

Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium

Hypertension Journal

Hypertension, Volume 81, Issue 2 , Page e7-e9, February 1, 2024.

article thumbnail

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

DAIC

In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.

Stroke 115
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures. Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , CAUTION - Limited by United States law to investigational use.

CMS 111
article thumbnail

American Heart Association Announces New 2024-2025 National Volunteer Leaders

DAIC

I am excited as the organization moves into our second century and to embrace new and innovative strategies to expand our research and understanding of how we can ensure cardiovascular health and total health for all.”

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.